Entity

Time filter

Source Type

BERLIN, Germany

Trademark
Mologen Ag | Date: 2004-05-03

Chemicals for use in industry and science, in particular proteins, enzymes and nucleic acids, as well as derivatives and/or chemical modifications and/or combinations thereof; gold salts for use in gene therapy. Medicines, namely, vaccines, anti-cancer DNA preparations, and cell based therapeutic preparations, namely, for use in the treatment of cancer, and for use of those preparations and vaccines in genetic immunization and genetic therapy; veterinary and medicinal preparations, namely, vaccines, anti-cancer DNA preparations, and cell based therapeutic preparations, namely, for use in the treatment of cancer, and for use of those preparations and vaccines in genetic immunization and genetic therapy; pharmaceutical preparations and pharmaceutical substances for gene therapy; pharmaceutical preparations for genetic vaccination and immunostimulation of humans and animals; biological preparations for medical use; vaccines.


Trademark
Mologen Ag, Mologen Forschungs and Mologen Gmbh | Date: 2004-05-04

Chemicals used in industry and science, namely, proteins, enzymes, nucleic acids, and modifications thereof for use in biology, medicine research, genetic engineering and genetic research; gross material product-grade, or GMP-grade, DNA for use in biology, medicine research, genetic engineering and genetic therapy research; enzymes for the modification of GMP-grade DNA for use in biology, medicine research, genetic engineering treatment of cancer research, genetic immunization and genetic therapy research; chemical preparations for use in the manufacture of pharmaceuticals for use in gene therapy. Medicines, pharmaceutical preparations and preparations for medical purposes, namely, substances for use in gene therapy; vaccines; gold and gold compounds for use in gene therapy. Medical services and genetic engineering; research and development for others in the field of medical procedures and medical apparatuses; scientific research in the fields of medicine, biology, gene technology, and genetic engineering.


Trademark
Mologen Ag | Date: 2006-03-14

[ Chemicals used in industry and science, namely, proteins, peptides, enzymes, saccharides and nucleic acids, and modifications thereof all for use in biology and genetic engineering, and none of the aforementioned goods used for or in relation to slimming products and dietetic products ]. Medicines and pharmaceutical preparations all for use in the immunostimulation treatment and pharmaceutical preparations for medical and veterinary medical purpose for immunostimulation treatment; vaccines; gold salts and compounds for use in vaccination of humans and animals none of the aforementioned goods used for or in relation to slimming products and dietetic products. [ Medical and sanitary instruments and apparatus, namely, syringes and needles for application of vaccines, in particular for the transfer of proteins, peptides, enzymes, saccharides and nucleic acids, as well as modifications thereof in humans and animals and none of the aforementioned goods used for or in relation to slimming products and dietetic products ]. Scientific research and development of methods and apparatus for medical and veterinary medical application in the field of vaccination and immunization; research and development of processes and equipment in the field of genetic engineering; research in the field of immunization of humans and animals; none of the aforementioned services used for or in relation to slimming products and dietetic products. [ Services in the field of medical application of vaccines and immunization of and for humans and animals ].


Grant
Agency: Cordis | Branch: FP7 | Program: CP-SICA | Phase: HEALTH-2007-2.3.4-2 | Award Amount: 4.10M | Year: 2009

This project will focus on the preclinical development of a DNA vaccine for human visceral leishmaniasis. The project is based upon the DNA vaccine technology and immunomodulators developed at Mologen AG (Berlin, Germany), which are in clinical development for cancer and 3-5 known antigens that already have demonstrated profiles of protection in animal models of leishmaniasis. Antigens will be selected on the basis of preset criteria to assure protection in high proportion of target populations and against many different species of Leishmania. In vitro and in vivo models will be used to evaluate the prophylactic and therapeutic efficacy of the DNA vehicle with selected antigens alone and in combination with and without immunomodulator. Full toxicology studies will be performed on selected candidate vaccines. Training in preclinical development and clinical trials (ICH-GCP) are an important part of the proposal. Sites will be selected and ready to initiate clinical trials at the end of this project (3 years).


Trademark
Mologen Ag | Date: 2015-08-25

Chemicals used in industry and science, namely, proteins, enzymes and nucleic acids, as well as derivatives and/or chemical modifications and/or combinations thereof; gold salts for use in gene therapy. Medicines for the treatment of cancer, autoimmune diseases or infectious diseases; pharmaceutical preparations for the treatment or prevention of cancer, autoimmune diseases or infectious diseases, chemical reagents for medical or veterinary purposes, chemical preparations for sanitary purposes; veterinary preparations for the treatment or prevention of cancer, autoimmune diseases or infectious diseases in mammals and medicinal preparations for the treatment or prevention of cancer, autoimmune diseases or infectious diseases; pharmaceutical substances for gene therapy; biological preparations for the treatment or prevention of cancer, autoimmune diseases or infectious diseases; vaccines.

Discover hidden collaborations